Glycemic variability: prognostic impact on acute ischemic stroke and the impact of corrective treatment for hyperglycemia. The GLIAS-III translational study.
Blanca FuentesSilvia Pastor-YborraRaquel Gutiérrez-ZúñigaNoemí González-Pérez de VillarElena de CelisJorge Rodríguez-PardoMari Carmen Gómez-de FrutosFernando Laso-GarcíaMaría Gutiérrez-FernándezMÁngeles Ortega-CasarrubiosAlfonso SotoMaría López-FernándezMaría SantamaríaNoemí Díez-GonzálezMar M FreijoBeatriz ZandioRaquel Delgado-MederosAna CallejaJuan Carlos Portilla-CuencaArturo LisbonaLaura Otero-OrtegaExuperio Díez-TejedorPublished in: Journal of translational medicine (2020)
The GLIAS-III study will be the first translational approach analyzing the prognostic influence of GV, evaluated by the use of subcutaneous glucose monitors, in acute stroke. Trial registration https://www.clinicaltrials.gov (NCT04001049).